Good Therapeutics, Inc. — Form D/A
Good Therapeutics, Inc. of SEATTLE, WA, a company, filed a Form D amendment with the SEC on 2020-05-21. The offering totals $22.3M, of which $22.3M was reported sold. Industry: Biotechnology.
Offering
- Filed: 2020-05-21
- Form: D/A
- Accession: 0001758604-20-000001
- Industry: Biotechnology
- Exemptions: 06b
- Total offering: $22.3M
- Amount sold: $22.3M
- Investors: 6
- Date of first sale: 2018-11-09
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-326349
Issuer
- Name: Good Therapeutics, Inc.
- CIK: 0001758604
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2016
- Address: 1616 Eastlake Avenue East, Suite 400, SEATTLE, WA, 98102
- Phone: 206-888-8485
Officers, directors & promoters (10)
| Name | Role | Location |
|---|
| Mitchell Mutz | Director | Seattle, WA |
| Karl Handelsman | Director | Grand Prairie, TX |
| Nicholas Walrod | Director | Minneapolis, MN |
| Diane Hollenbaugh | Executive Officer | Seattle, WA |
| John Mulligan | Director | Seattle, WA |
| John Mulligan | Executive Officer | Seattle, WA |
| John Mulligan | Promoter | Seattle, WA |
| Monique Schiersing | Director | Seattle, WA |
| John McKearn | Director | Seattle, WA |
| Neela Patel | Executive Officer | Seattle, WA |
Other filings by this issuer (3)
More